Good morning :)
Place Order
Add to Watchlist

Aarti Drugs Ltd

AARTIDRUGS

Aarti Drugs Ltd

AARTIDRUGS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,190 cr, stock is ranked 850
Moderate RiskStock is 2.01x as volatile as Nifty
455.150.00% (+0.00)
455.150.00% (+0.00)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,190 cr, stock is ranked 850
Moderate RiskStock is 2.01x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,190 cr, stock is ranked 850
Moderate RiskStock is 2.01x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.513.270.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.

Investor Presentation

View older 

Sep 20, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.08%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.71% to 0.67%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 13.82%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,139.841,199.171,244.681,567.121,812.042,162.572,499.972,718.242,532.612,384.94
Raw Materialssubtract758.16765.89821.921,026.311,210.601,310.661,750.061,863.711,626.102,091.64
Power & Fuel Costsubtract53.9359.4271.4284.39103.8398.20128.34156.10154.31
Employee Costsubtract40.1947.9552.1454.5561.3565.8869.3080.4390.60
Selling & Administrative Expensessubtract37.9241.7447.6054.6680.1698.43104.24104.6695.12
Operating & Other expensessubtract69.8389.6948.68130.1284.63144.28104.11201.71241.61
Depreciation/Amortizationsubtract36.5338.4640.0642.5648.7549.8850.0550.3251.4553.34
Interest & Other Itemssubtract48.0240.0238.3643.5137.4226.2323.9137.1437.8934.37
Taxes & Other Itemssubtract26.5534.2142.2041.2743.8988.6064.9257.8864.1053.30
EPS7.098.518.679.5115.0830.0922.0717.9618.5816.56
DPS1.690.250.250.250.502.501.001.001.001.00
Payout ratio0.240.030.030.030.030.080.050.060.050.06

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 7PDF
May 9PDF
Jan 31PDF
FY 2023

Annual report

PDF

Investor Presentation

May 2PDF
Jan 27PDF
Oct 20PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Jul 21PDF
FY 2025

Annual Report Pending

Investor Presentation

Sep 20PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aarti Drugs Ltd24.443.270.22%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare AARTIDRUGS with any stock or ETF
Compare AARTIDRUGS with any stock or ETF
AARTIDRUGS
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.49%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding55.64%6.25%1.58%2.50%34.02%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep1.96%2.33%2.10%2.56%2.96%2.50%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Aarti Drugs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
DSP Small Cap Fund - Growth - Direct Plan

Growth
5.3988%1.40%-0.07%28/81 (-1)
Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct Plan

Growth
0.0920%0.22%-0.05%253/309 (-2)
DSP Value Fund - Growth - Direct Plan

Growth
0.0812%0.38%-0.02%34/75 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AARTIDRUGS has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.22%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.19 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 6, 2024

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 6, 2024

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 8, 2023

Cash Dividend

Ex DateEx DateFeb 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 9, 2022

Cash Dividend

Ex DateEx DateNov 3, 2020

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Nov 3, 2020

Cash Dividend

Ex DateEx DateFeb 17, 2020

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Feb 17, 2020

News & Opinions
Earnings
Aarti Drugs consolidated net profit declines 11.57% in the September 2024 quarter

Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales598.33641.54 -7 OPM %11.2111.92 - PBDT59.6068.88 -13 PBT45.8856.27 -18 NP35.0139.59 -12 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aarti Drugs to conduct board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Aarti Drugs gains after arm receives UK MHRA GMP Compliance Certificate

The company said that there are no financial or material impacts as of now. With the GMP compliance, Pinnacle is positioned to export its formulations to the UK market. The firm stated that there have been no violations or alleged contraventions regarding its operations. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Aarti Drugs' Maharashtra facility gets 7 observations from USFDA

The API inspection was conducted from 12 September to 20 September 2024. At the conclusion of the inspection, the USFDA issued a Form FDA 483, which included seven inspectional observations. Notably, none of the observations were related to data integrity. The company stated that it will work closely with USFDA to resolve all points raised during the inspection. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. The scrip advanced 1.16% to ends at Rs 524.80 on Friday, 20 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Aarti Drugs extends buyback offer period

Aarti Drugs announced that the bidding process of buyback offer will remain open on Monday, 16 September 2024 (SEBI working day) and close tender offer on Thursday, 19 September 2024 (except Wednesday, 18 September 2024, being holiday). Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Aarti Drugs AGM scheduled

Aarti Drugs announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Board of Aarti Drugs approves buyback of shares up to Rs 59.85 cr

The Board of Aarti Drugs at its meeting held on 26 August 2024 has approved buyback of up to 6,65,000 equity shares of face value of Rs 10 each at a price of Rs 900 per share payable in cash for an aggregate amount of up to Rs 59.85 crore. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Aarti Drugs fixes record date for buyback of shares

Aarti Drugs has fixed 05 September 2024 as record date for proposed buyback of shares. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Aarti Drugs hit 52-week high as board OKs Rs 60-cr share buyback

The buyback price fixed at Rs 900 per equity share, representing a 59.66% premium to Friday's closing price of Rs 563.70 on the BSE. The pharmaceutical company will buyback up to 6, 65,000 fully paid-up equity shares, representing up to 0.72% of the total paid-up equity shares of the firm. The buyback offer size represents 5.16% and 4.74% of the fully paid- up equity share capital and free reserves of the company based on the audited standalone and consolidated balance sheet of the company as on 31 March 2024, respectively. The company has fixed 5 September 2024 as the record date for the proposed buyback. The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the buyback regulations, said the firm. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. The counter hit a 52-week high of Rs 632.10 in today's intraday session. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Aarti Drugs soars on share buyback proposal

The announcement was made after market hours yesterday. Aarti Drugs forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its whollyowned subsidiary-Pinnacle Life Science Private. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. Powered by Capital Market - Live

3 months agoCapital Market - Live